SBL
MITO

Sargent Bickham Lagudis’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Sargent Bickham Lagudis’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,714
Closed -$20K – 1042
2021
Q3 		$20K Hold
14,714
– – ﹤0.01% 605
2021
Q2 		$23K Buy
+14,714
New +$20.5K ﹤0.01% 590

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Sargent Bickham Lagudis's MITO Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2021, closing a stake of 14,714 shares — an estimated $20K sold.

Sargent Bickham Lagudis first reported a position in MITO in Q2 2021 and held it in 2 quarters. The position peaked at $23K in Q2 2021. 15 funds tracked by Wall St. Rank hold MITO as of Q4 2021.

  • Sargent Bickham Lagudis reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 14,714 Stealth BioTherapeutics Corp. ADS shares in Q4 2021, an estimated $20K.
  • Sargent Bickham Lagudis first reported a position in Stealth BioTherapeutics Corp. ADS in Q2 2021 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Stealth BioTherapeutics Corp. ADS position peaked at $23K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.